Ebn Sina Medical and BeiGene Join Forces to Transform Cancer Care in Qatar
Doha, Qatar – [Insert Date] – In a landmark move to improve cancer treatment access and quality in Qatar, Ebn Sina Medical, a subsidiary of Aamal Company Q.P.S.C, has entered a strategic partnership with BeiGene, a leading global biotechnology company known for its groundbreaking cancer therapies.
This alliance will introduce BeiGene’s innovative oncology treatments into the Qatari healthcare system, enabling better outcomes for patients battling cancer and reinforcing Qatar’s vision to become a regional healthcare hub.
Expanding Cancer Treatment Options in Qatar
Founded in 1971, Ebn Sina Medical is one of Qatar’s most trusted names in the healthcare sector. The company plays a key role in importing, distributing, and marketing pharmaceutical products, medical equipment, and healthcare solutions. With strong ties to global medical suppliers, Ebn Sina is committed to delivering quality healthcare solutions that improve lives across the country.
On the other side of the partnership is BeiGene, a biotechnology firm that started in China in 2010 and has since grown into an international leader in oncology research. The company now boasts over 17 approved treatments and an extensive pipeline addressing both blood cancers and solid tumors.
The collaboration between Ebn Sina and BeiGene is expected to help bridge the gap in availability of world-class cancer therapies in Qatar, making these life-saving treatments more affordable, accessible, and effective.
“This partnership is a milestone in our mission to bring cutting-edge treatments to patients in Qatar,” said a spokesperson from Ebn Sina Medical. “We’re proud to work with BeiGene to offer hope and healing to those affected by cancer.”
A Step Forward in Regional Healthcare Strategy
This strategic alliance also aligns with BeiGene’s broader mission to expand into the Middle East and North Africa (MENA) region. The company opened its first MENA regional office at Dubai Science Park in October 2023, laying the groundwork for its long-term commitment to serving patients across the region.
According to Jurij Petrin, Head of New Market Development at BeiGene:
“Our expansion into the MENA region is a major part of our global growth strategy and demonstrates our commitment to bringing innovative and affordable therapies to more patients around the world.”
With cancer cases on the rise globally, and particularly in fast-growing populations across the Gulf, the need for high-quality treatment options is urgent. BeiGene aims to address 80% of global cancer incidences, focusing on developing therapies that can meet regional needs without compromising on quality or innovation.
Supporting Qatar’s Vision for World-Class Healthcare
Qatar has been heavily investing in strengthening its healthcare system. Government-led initiatives, public-private partnerships, and international collaborations are all part of a national vision to elevate the standard of healthcare in the country.
This new partnership adds to Ebn Sina Medical’s growing list of strategic collaborations. In May 2024, the company renewed its long-standing agreement with Novo Nordisk, the Danish pharma giant known for diabetes, obesity, and hemophilia care. That deal reinforced Qatar’s access to top-tier chronic disease management products.
Earlier, in 2018, Ebn Sina teamed up with CinnaGen, a Turkish biopharmaceutical company, to bring advanced biotech drugs to Qatar for treating cancer, multiple sclerosis, and autoimmune diseases. That collaboration not only strengthened trade ties but also expanded patient access to complex and rare disease treatments.
These previous initiatives set the stage for the current BeiGene agreement, which represents a major leap forward in Qatar’s fight against cancer.
Making Lifesaving Therapies More Accessible
With cancer being one of the leading causes of death worldwide, early diagnosis and access to modern treatments are crucial. Unfortunately, many patients in the Middle East still face barriers to advanced care, either due to lack of availability or high costs.
BeiGene’s approach of delivering high-quality yet cost-effective solutions fits perfectly with the goals of Qatar’s Ministry of Public Health and Ebn Sina Medical’s commitment to improving population health.
By leveraging Ebn Sina’s deep market knowledge, regulatory experience, and distribution capabilities, the partnership ensures BeiGene’s treatments will be swiftly and safely integrated into the country’s healthcare framework.
Looking Ahead: Innovation, Collaboration, and Hope
The Ebn Sina–BeiGene partnership is expected to open doors to even more opportunities, including:
- Clinical trials for oncology drugs
- Medical education and training for local healthcare providers
- Public awareness campaigns on early cancer detection
- Joint research and development projects in precision medicine
These initiatives will not only enhance patient care but also promote knowledge exchange and innovation, helping Qatar become a regional center of medical excellence.
“This partnership is more than just a business agreement,” said a regional healthcare analyst. “It’s a collaborative mission to change lives, save lives, and lead the future of cancer treatment in the Gulf.”
Final Thoughts
In an era where collaboration drives progress, the partnership between Ebn Sina Medical and BeiGene stands out as a model of global cooperation for local impact.
It reflects Qatar’s determination to deliver top-quality healthcare services and positions the country as a forward-thinking leader in the region’s medical landscape. As this partnership unfolds, patients, doctors, and healthcare providers across Qatar can look forward to a brighter, healthier future powered by science, compassion, and innovation.
Do follow gulf magazine on Instagram
for more information click here
